Form 4: Achieve Life Sciences Executive Cindy Jacobs Reports Stock Transactions

Cindy Jacobs, President & CMO of Achieve Life Sciences, reports the acquisition of 16,250 shares of common stock upon settlement of performance restricted stock units and the disposal of 3,957 shares to cover tax liabilities.

Summary

• On April 19, 2024, Cindy Jacobs, President & CMO of Achieve Life Sciences, acquired 16,250 shares of common stock upon the settlement of performance restricted stock units (PRSUs).
• The price per share for the acquisition was $0.
• Also on April 19, 2024, Ms. Jacobs disposed of 3,957 shares of common stock at a price of $4.51 per share to satisfy tax liabilities related to the settlement of the PRSUs.
• Following these transactions, Ms. Jacobs beneficially owns 30,554 shares of Achieve Life Sciences common stock.

Sentiment

Score: 6

Explanation: Neutral sentiment as the filing reflects routine stock transactions related to executive compensation. The acquisition of shares through PRSU settlement is a positive sign, but the sale to cover taxes balances it out.

Positives

• The acquisition of shares upon PRSU settlement indicates that performance milestones were likely achieved.

Negatives

• The disposal of shares to cover tax liabilities reduces the overall increase in holdings.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders, like officers and directors, trade their company's stock. These filings provide transparency into insider transactions and can be monitored by investors for insights into management's perspective on the company's value and prospects.

Stakeholder Impact

• The transactions have a minor impact on shareholders as they reflect insider trading activity related to compensation.

Key Dates